12:00 AM
 | 
Mar 15, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/12 cls
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) Jefferies Thomas Wei Price target Buy 2% $20.26
Wei raised his target to $30 from $27 after the company disclosed in an SEC filing that it plans to submit an NDA this year for metreleptin to treat lipodystrophy. He estimates the market opportunity at $150-$300M. Amylin has exclusive, worldwide rights from Amgen Inc. (NASDAQ:AMGN) to the recombinant form of human leptin (see SciBX: Science-Business eXchange, March 11).
Cerus Corp. (NASDAQ:CERS) Baird Christopher Raymond Upgrade Market outperform (from neutral) 32% $3.05
Raymond also raised his target to $5 from $3. He thinks the price does not fully reflect the market potential of Cerus' Intercept Blood System to inactivate blood-borne pathogens in donated blood components. He noted the company has posted three consecutive quarters of revenue increases for Intercept for plasma and platelets components, which are marketed in the EU, Middle East, Russia and certain other countries. Raymond added that the market appears to have...

Read the full 1077 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >